Syreon Research Institute, Budapest, Hungary.
Center for Health Technology Assessment and Pharmacoeconomic Research, Faculty of Pharmacy, University of Pécs, Pécs, Hungary.
Health Econ. 2022 Sep;31 Suppl 1(Suppl 1):195-206. doi: 10.1002/hec.4504. Epub 2022 Mar 23.
Experiences with coverage with evidence development (CED) schemes are fairly limited in Central and Eastern European (CEE) countries, which are usually late adopters of new health technologies. Our aim was to put forward recommendations on how CEE health technology assessment bodies and payer organizations can apply CED to reduce decision uncertainty on reimbursement of medical devices, with a particular focus on transferring the structure and data from CED schemes in early technology adopter countries in Western Europe. Structured interviews on the practices and feasibility of transferring CED schemes were conducted and subsequently, a draft tool for the systematic classification of decision alternatives and recommendations was developed. The decision tool was reviewed in a focus group discussion and validated within a wider group of CEE experts in a virtual workshop. Transferability assessment is needed in case of (1) joint implementation of a CED scheme; (2) transferring the structure of an existing CED scheme to a CEE country; (3) reimbursement decisions that are linked to outcomes of an ongoing CED scheme in another country and (4) real-world evidence transferred from completed CED schemes. Efficient use of available resources may be improved by adequately transferring evidence and policy tools from early technology adopter countries.
在中东欧(CEE)国家,有证据的药物开发(CED)方案的经验相当有限,这些国家通常是新技术的后期采用者。我们的目的是提出建议,说明 CEE 卫生技术评估机构和支付者组织如何应用 CED 来减少医疗器械报销决策的不确定性,特别关注从西欧早期技术采用者国家的 CED 方案中转移结构和数据。对 CED 方案的实践和可行性进行了结构化访谈,随后开发了一个用于系统分类决策替代方案和建议的工具草案。该决策工具在焦点小组讨论中进行了审查,并在一个虚拟研讨会上由更广泛的 CEE 专家群体进行了验证。在以下情况下需要进行可转移性评估:(1) 联合实施 CED 方案;(2) 将现有 CED 方案的结构转移到 CEE 国家;(3) 与另一个国家正在进行的 CED 方案结果相关的报销决策;(4) 从已完成的 CED 方案中转移真实世界证据。通过从早期技术采用者国家充分转移证据和政策工具,可以提高现有资源的使用效率。